Abstract P403: Healthcare Resource Utilization and Costs Associated With Oral Anticoagulant Reversal With Idarucizumab or Andexanet Alfa for Patients Hospitalized With Life-Threatening Bleeding Events

Alex C. Spyropoulos,Briain Ó Hartaigh,Zhun Cao,Harjeet S Caberwal,Craig Lipkin,Michaela Petrini,Cheng Wang

Abstract P403: Healthcare Resource Utilization and Costs Associated With Oral Anticoagulant Reversal With Idarucizumab or Andexanet Alfa for Patients Hospitalized With Life-Threatening Bleeding Events

2021

Alex C. Spyropoulos
Briain Ó Hartaigh
Zhun Cao
Harjeet S Caberwal
Craig Lipkin
Michaela Petrini
Cheng Wang

Introduction: This study compared healthcare resource utilization and costs associated with the use of idarucizumab for the reversal of dabigatran, and andexanet alfa for the reversal of rivaroxaba...

Keywords:

Intracerebral hemorrhage
Andexanet alfa
Intensive care medicine
Dabigatran
Health care
Venous thrombosis
Medicine
Idarucizumab
Atrial fibrillation
resource utilization

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations